Safi Biotherapeutics Tailored blood, at scale.
Total raised: $5M
Funding Rounds 1
| Date | Series | Amount | Investors |
| 18.09.2024 | Seed | $5M | - |
Mentions in press and media 7
| Date | Title | Description |
| 24.04.2025 | Safi Biotherapeutics Awarded NIH STTR Grant to Improve Blood Transfusion Safety | Safi to bulk manufacture Children’s Hospital of Philadelphia’s iPSC-derived RBCs with rare antigen profiles as diagnostic tools for alloimmunized patients We are pleased to partner with Dr. Chou on this proof-of-principle to scale the manuf... |
| 18.09.2024 | Safi Biotherapeutics: Manufactured Red Blood Cells Company Raises $5 Million (Seed) | Safi Biotherapeutics—a company launched by former DARPA, Vertex, MIT, and MGH leaders—is leading the development of manufactured red blood cells (mRBCs) as an alternative to donor blood transfusions. The company recently announced a $5 mill... |
| 12.09.2024 | Safi Biotherapeutics Raises $5M in Seed Funding | Safi Biotherapeutics, a Cambridge, MA-based developer of manufactured red blood cells (mRBCs) as an alternative to donor blood transfusions, raised $5M in seed funding. The round, which complements over $15M in funding received to date from... |
| 11.09.2024 | US government-backed biotech startup Safi Biotherapeutics is developing lab-grown blood to address shortages | Blood shortages in the United States are becoming a growing concern as fewer people are donating due to busy schedules, travel, and health issues. This shortfall affects critical medical procedures, such as surgeries, cancer treatments, and... |
| 11.09.2024 | Safi Biotherapeutics Secures $5M in Seed Funding to Accelerate Plans to Grow Blood for Acute and Chronic Transfusions | High density mRBCs Developer of world-leading capabilities in the hyper-efficient production of manufactured red blood cells at viable economics. The challenge has been whether we can make enough of these cells cheaply enough to be viable a... |
| 05.01.2024 | Safi Biotherapeutics Solidifies Leading Position in Red Blood Cell Biomanufacturing with Acquisition of EryPharm Assets | This acquisition represents a landmark moment for Safi and the entire biotechnology industry, propelling Safi's mission to provide a sustainable and scalable solution for red blood cell production” — Safi CEO and Co-founder Doug McConnellCA... |
| - | Safi Biosolutions | “Safi Biotherapeutics is developing blood cell products and therapeutics through novel and proprietary cell manufacturing and source expansion techniques.” |